December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief found that post-drug syndromes are under-recognized in current pharmacovigilance systems, leading to inadequate risk assessments and prolonged patient harm from persistent drug-induced conditions.
January 2020 in “Advances in Sexual Medicine” This study suggests that female sexual dysfunction is not significantly associated with female pattern hair loss, but it may be more strongly influenced by age and parity in premenopausal women.
December 2025 in “Zenodo (CERN European Organization for Nuclear Research)” This policy brief highlights that post-drug syndromes remain under-recognized in pharmacovigilance, leading to inadequate risk assessments and patient care. It identifies systemic failures in current frameworks and recommends actions to improve long-term drug safety monitoring and education, affecting public health outcomes significantly.
40 citations
,
September 2019 in “Molecular and Cellular Endocrinology” This paper discusses mechanisms by which various chemicals disrupt male sexual differentiation, concluding that mixture risk assessments should include a broader set of compounds beyond phthalates to address cumulative reproductive health risks.
March 2026 in “RS Global journals (RS Global Sp. z O.O.)” This review reports that while finasteride effectively treats androgenetic alopecia and benign prostatic hyperplasia, persistent adverse effects on sexual, psychological, and metabolic health have been noted, highlighting the need for ongoing research and careful risk assessment for safer clinical usage.
